Jump Financial LLC Takes $1.05 Million Position in Amgen Inc. (NASDAQ:AMGN)

Jump Financial LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,034 shares of the medical research company's stock, valued at approximately $1,051,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the 4th quarter valued at about $25,000. Ritter Daniher Financial Advisory LLC DE raised its stake in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC acquired a new stake in Amgen in the 4th quarter valued at $34,000. Atala Financial Inc acquired a new position in Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $0.90 during trading hours on Friday, reaching $280.74. The stock had a trading volume of 1,234,911 shares, compared to its average volume of 3,168,551. The firm has a market cap of $150.94 billion, a price-to-earnings ratio of 37.18, a PEG ratio of 2.63 and a beta of 0.59. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a 50-day moving average of $301.75 and a 200-day moving average of $293.08. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is presently 126.09%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now directly owns 36,922 shares in the company, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on shares of Amgen in a research note on Tuesday. They set a "neutral" rating and a $305.00 target price on the stock. Piper Sandler Companies restated an "overweight" rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Truist Financial dropped their price objective on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Finally, StockNews.com cut shares of Amgen from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 17th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.